Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001864260 | SCV002125671 | uncertain significance | Cohen syndrome | 2022-06-29 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 1707 of the VPS13B protein (p.Lys1707Glu). This variant is present in population databases (no rsID available, gnomAD 0.004%). This missense change has been observed in individual(s) with VPS13B-related conditions (PMID: 30290665). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV003401783 | SCV004119908 | uncertain significance | VPS13B-related disorder | 2023-07-04 | criteria provided, single submitter | clinical testing | The VPS13B c.5044A>G variant is predicted to result in the amino acid substitution p.Lys1682Glu. This variant, along with variants in multiple other genes, was reported in an individual with primary immunodeficiency [Reported as VPS13B c.5119A>G (p.Lys1707Glu) via NM_017890.4, Chi et al. 2018. PubMed ID: 30290665]. This variant is reported in 0.0040% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/8-100587980-A-G). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |